439117-41-6Relevant articles and documents
PYRROLIDINE THROMBIN INHIBITORS
-
Page/Page column 26, (2014/03/21)
Compounds of the invention, which may be useful in inhibiting thrombin and associated thrombotic occlusions, have the following structure: (I) or a pharmaceutically acceptable salt thereof, wherein R is a heterocycle or -(CR4R5)1-2NH2 , wherein R4 and R5,
Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability
Morrissette, Matthew M.,Stauffer, Kenneth J.,Williams, Peter D.,Lyle, Terry A.,Vacca, Joseph P.,Krueger, Julie A.,Lewis, S. Dale,Lucas, Bobby J.,Wong, Bradley K.,White, Rebecca B.,Miller-Stein, Cynthia,Lyle, Elizabeth A.,Wallace, Audrey A.,Leonard, Yvonne M.,Welsh, Denise C.,Lynch, Joseph J.,McMasters, Daniel R.
, p. 4161 - 4164 (2007/10/03)
Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to
Stereoselective synthesis of a potent thrombin inhibitor by a novel P2-P3 lactone ring opening
Nelson, Todd D.,LeBlond, Carl R.,Frantz, Doug E.,Matty, Louis,Mitten, Jeffrey V.,Weaver, Damian G.,Moore, Jeffrey C.,Kim, Jaehon M.,Boyd, Russell,Kim, Pei-Yi,Gbewonyo, Kodzo,Brower, Mark,Sturr, Michael,McLaughlin, Kathleen,McMasters, Daniel R.,Kress, Michael H.,McNamara, James M.,Dolling, Ulf H.
, p. 3620 - 3627 (2007/10/03)
The concise synthesis of a potent thrombin inhibitor was accomplished by a mild lactone aminolysis between an orthogonally protected bis-benzylic amine and a diastereomerically pure lactone. The lactone was synthesized by the condensation of L-proline met
Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position
Rittle, Kenneth E.,Barrow, James C.,Cutrona, Kellie J.,Glass, Kristen L.,Krueger, Julie A.,Kuo, Lawrence C.,Lewis, S. Dale,Lucas, Bobby J.,McMasters, Daniel R.,Morrissette, Matthew M.,Nantermet, Philippe G.,Newton, Christina L.,Sanders, William M.,Yan, Youwei,Vacca, Joseph P.,Selnick, Harold G.
, p. 3477 - 3482 (2007/10/03)
Thrombin inhibitors incorporating o-aminoalkylbenzylamides in the P1 position were designed, synthesized and found to have enhanced potency and selectivity in several different structural classes. X-ray crystallographic analysis of compound 24 bound in the α-thrombin-hirugen complex provides an explanation for these unanticipated results.
Thrombin inhibitors
-
, (2008/06/13)
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, e.g. 1-(3(S)-Cyclopropyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide, and 1-(3-Cyclopropyl-3-methyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide.
Thrombin inhibitors
-
, (2008/06/13)
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, e.g. 1-(3(S)-Cyclopropyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide, and 1-(3-Cyclopropyl-3-methyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide.
Thrombin inhibitors
-
, (2008/06/13)
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, e.g. where R3 is —CH2NH2, —CH2CH2NH2, or —CH2NHC(O)OC(CH3)3.
